primaquine has been researched along with Disease Models, Animal in 42 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) are at risk for developing hemolytic anemia when given the antimalarial drug primaquine (PQ)." | 7.83 | Single-Dose Primaquine in a Preclinical Model of Glucose-6-Phosphate Dehydrogenase Deficiency: Implications for Use in Malaria Transmission-Blocking Programs. ( Baresel, PC; Campo, B; Marcsisin, SR; Reichard, GA; Rochford, R; Sousa, J; Tekwani, BL; Vuong, CT; Walker, LA; Wickham, KS, 2016) |
| "Primaquine (PQ) is one of the most widely used antimalarial and is the only available drug till date to combat relapsing form of malaria especially in case of Plasmodium vivax and Plasmodium ovale." | 7.74 | Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. ( Singh, KK; Vingkar, SK, 2008) |
| "The aim of this preliminary study was to investigate the potential use of the transdermal route for primaquine administration in the treatment of malaria." | 7.69 | Preliminary evaluation of primaquine activity on rodent malaria model after transdermal administration. ( Couarraze, G; Deharo, E; Landau, I; Mayorga, P, 1997) |
| "The liver-stage anti-malarial activity of primaquine and other 8-aminoquinoline molecules has been linked to bio-activation through CYP 2D6 metabolism." | 3.83 | Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants. ( Hickman, M; Jin, X; Kreishman-Deitrick, M; Li, Q; Luong, TL; Marcsisin, SR; Nelson, J; Paris, R; Potter, B; Potter, C; Pybus, BS; Reichard, G; Smith, PL; Sousa, J; Vuong, C; Xie, L; Zhang, J; Zhang, P, 2016) |
| "Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) are at risk for developing hemolytic anemia when given the antimalarial drug primaquine (PQ)." | 3.83 | Single-Dose Primaquine in a Preclinical Model of Glucose-6-Phosphate Dehydrogenase Deficiency: Implications for Use in Malaria Transmission-Blocking Programs. ( Baresel, PC; Campo, B; Marcsisin, SR; Reichard, GA; Rochford, R; Sousa, J; Tekwani, BL; Vuong, CT; Walker, LA; Wickham, KS, 2016) |
| "Due to the ability of the 8-aminoquinolines (8AQs) to kill different stages of the malaria parasite, primaquine (PQ) and tafenoquine (TQ) are vital for causal prophylaxis and the eradication of erythrocytic Plasmodium sp." | 3.83 | Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei. ( Berman, J; Caridha, D; Dickson, SP; Hickman, M; Lee, PJ; Li, Q; Marcsisin, SR; Milner, EE; Read, LT; Roncal, N; Vesely, BA; Xie, LH; Zhang, J; Zhang, P, 2016) |
| "Primaquine (PQ) remains the sole available drug to prevent relapse of Plasmodium vivax malaria more than 60 years after licensure." | 3.80 | Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta). ( Gettyacamin, M; Imerbsin, R; Khemawoot, P; Lanteri, C; Nanayakkara, NP; Ohrt, C; Sampath, A; Saunders, D; Siripokasupkul, R; Teja-Isavadharm, P; Tekwani, BL; Vanachayangkul, P; Walker, L, 2014) |
| " After sporozoite inoculation and blood-stage cure of initial parasitemia with chloroquine, rhesus macaques were treated on subsequent relapses with chloroquine in conjunction with test regimens of approved drugs." | 3.78 | Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. ( Bennett, K; Deye, GA; Fracisco, S; Gettayacamin, M; Hansukjariya, P; Im-erbsin, R; Macareo, L; Magill, AJ; Ohrt, C; Rothstein, Y; Sattabongkot, J, 2012) |
| "Primaquine is the drug of choice for the radical cure of Plasmodium vivax malaria, but possesses serious side effects." | 3.74 | Synthesis and evaluation of naphthyridine compounds as antimalarial agents. ( Gudise, C; Kong, Y; Meng, L; Smith, E; Wei, L; Zhang, Q; Zhu, S, 2007) |
| "Primaquine (PQ) is one of the most widely used antimalarial and is the only available drug till date to combat relapsing form of malaria especially in case of Plasmodium vivax and Plasmodium ovale." | 3.74 | Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine. ( Singh, KK; Vingkar, SK, 2008) |
| "The influence of combinations containing the blood schizontocides chloroquine (CQ) or mefloquine (MEF), together with the 8-aminoquinolines (8AQ) primaquine (PQ) or the new, long-acting compound, tafenoquine (TAF), on the rate of selection of resistance to the individual compounds was examined using the asexual, intra-erythrocytic stages in rodent malaria models." | 3.72 | The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines. ( Peters, W; Robinson, BL; Stewart, LB, 2003) |
| "The aim of this preliminary study was to investigate the potential use of the transdermal route for primaquine administration in the treatment of malaria." | 3.69 | Preliminary evaluation of primaquine activity on rodent malaria model after transdermal administration. ( Couarraze, G; Deharo, E; Landau, I; Mayorga, P, 1997) |
| "Three standard antimalarials pyrimethamine, primaquine and quinine were tested against P." | 3.67 | Gametocytocidal and sporontocidal activity of some standard antimalarials on P. berghei (NK 65) infection M. natalensis. ( Pal, NL; Rastogi, M; Sen, AB, 1989) |
| "Upon primaquine treatment, elimination of gametocytes from peripheral blood and from sequestration sites was observed, providing a proof of concept that these mice can be used for testing drugs." | 1.43 | A humanized mouse model for sequestration of Plasmodium falciparum sexual stages and in vivo evaluation of gametocytidal drugs. ( Cisteró, P; Duffier, Y; Dupuy, F; Fiette, L; Jouvion, G; Lavazec, C; Lorthiois, A; Mayor, A; Mazier, D; Moreno Sabater, A, 2016) |
| "Plasmodium vivax malaria is characterized by periodic relapses of symptomatic blood stage parasite infections likely initiated by activation of dormant liver stage parasites-hypnozoites." | 1.42 | Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. ( Adams, JH; Baldwin, M; Camargo, N; Fishbaugher, M; Kangwanrangsan, N; Kappe, SH; Kaushansky, A; Lakshmanan, V; Lindner, SE; Mikolajczak, SA; Prachumsri, J; Rezakhani, N; Roobsoong, W; Sattabongkot, J; Singh, N; Vaughan, AM; Yimamnuaychok, N, 2015) |
| "Methemoglobin, a toxic ferric form of hemoglobin, is continuously formed in normal erythrocytes, but during abnormal situations in situ, the level is enhanced." | 1.31 | A simple and rapid evaluation of methemoglobin toxicity of 8-aminoquinolines and related compounds. ( Jain, GK; Pandey, VC; Puri, SK; Singh, S; Srivastava, P, 2000) |
| " These studies suggest that higher doses of 8-aminoquinolines administered at appropriate intervals may be as effective as continuous dosing for prophylaxis of P." | 1.28 | Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats. ( Bartlett, MS; Berman, JD; Dean, RA; Ellis, WY; Milhous, WK; Queener, SF; Smith, JW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (23.81) | 18.7374 |
| 1990's | 6 (14.29) | 18.2507 |
| 2000's | 5 (11.90) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 4 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, S | 1 |
| Zhang, Q | 1 |
| Gudise, C | 1 |
| Meng, L | 1 |
| Wei, L | 1 |
| Smith, E | 1 |
| Kong, Y | 1 |
| Lauinger, IL | 1 |
| Vivas, L | 1 |
| Perozzo, R | 1 |
| Stairiker, C | 1 |
| Tarun, A | 1 |
| Zloh, M | 1 |
| Zhang, X | 1 |
| Xu, H | 1 |
| Tonge, PJ | 1 |
| Franzblau, SG | 1 |
| Pham, DH | 1 |
| Esguerra, CV | 1 |
| Crawford, AD | 1 |
| Maes, L | 1 |
| Tasdemir, D | 1 |
| Mayoka, G | 1 |
| Njoroge, M | 1 |
| Okombo, J | 1 |
| Gibhard, L | 1 |
| Sanches-Vaz, M | 1 |
| Fontinha, D | 1 |
| Birkholtz, LM | 1 |
| Reader, J | 1 |
| van der Watt, M | 1 |
| Coetzer, TL | 1 |
| Lauterbach, S | 1 |
| Churchyard, A | 1 |
| Bezuidenhout, B | 1 |
| Egan, TJ | 1 |
| Yeates, C | 1 |
| Wittlin, S | 1 |
| Prudêncio, M | 1 |
| Chibale, K | 1 |
| Dodean, RA | 2 |
| Kancharla, P | 2 |
| Li, Y | 2 |
| Melendez, V | 2 |
| Read, L | 2 |
| Bane, CE | 2 |
| Vesely, B | 2 |
| Kreishman-Deitrick, M | 3 |
| Black, C | 2 |
| Li, Q | 5 |
| Sciotti, RJ | 2 |
| Olmeda, R | 2 |
| Luong, TL | 3 |
| Gaona, H | 2 |
| Potter, B | 3 |
| Sousa, J | 5 |
| Marcsisin, S | 2 |
| Caridha, D | 4 |
| Xie, L | 3 |
| Vuong, C | 3 |
| Zeng, Q | 2 |
| Zhang, J | 4 |
| Zhang, P | 5 |
| Lin, H | 2 |
| Butler, K | 2 |
| Roncal, N | 3 |
| Gaynor-Ohnstad, L | 2 |
| Leed, SE | 2 |
| Nolan, C | 2 |
| Huezo, SJ | 1 |
| Rasmussen, SA | 2 |
| Stephens, MT | 1 |
| Tan, JC | 1 |
| Cooper, RA | 2 |
| Smilkstein, MJ | 2 |
| Pou, S | 2 |
| Winter, RW | 1 |
| Riscoe, MK | 2 |
| Kelly, JX | 2 |
| Pybus, B | 2 |
| Ceja, FG | 1 |
| Tumwebaze, PK | 1 |
| Rosenthal, PJ | 1 |
| Mu, J | 1 |
| Bayles, BR | 1 |
| Reynolds, KA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Flaherty, S | 1 |
| Strauch, P | 1 |
| Maktabi, M | 1 |
| Pybus, BS | 2 |
| Reichard, G | 2 |
| Walker, LA | 2 |
| Rochford, R | 2 |
| Vera, IM | 1 |
| Grilo Ruivo, MT | 1 |
| Lemos Rocha, LF | 1 |
| Marques, S | 1 |
| Bhatia, SN | 1 |
| Mota, MM | 1 |
| Mancio-Silva, L | 1 |
| Thome, R | 2 |
| Casella, G | 1 |
| Lotfi, N | 1 |
| Ishikawa, LWL | 1 |
| Wang, Q | 1 |
| Ciric, B | 1 |
| Zhang, GX | 1 |
| Rostami, A | 1 |
| Gao, X | 1 |
| Ishida, H | 1 |
| Amnuaysirikul, J | 1 |
| Weina, PJ | 1 |
| Grogl, M | 1 |
| O'Neil, MT | 1 |
| Ohrt, C | 4 |
| Hickman, M | 3 |
| Magill, AJ | 2 |
| Ray, P | 1 |
| Lödige, M | 1 |
| Lewis, MD | 1 |
| Paulsen, ES | 1 |
| Esch, HL | 1 |
| Pradel, G | 1 |
| Lehmann, L | 1 |
| Brun, R | 1 |
| Bringmann, G | 1 |
| Mueller, AK | 1 |
| DiTusa, C | 1 |
| Kozar, MP | 1 |
| Berman, J | 2 |
| Gettayacamin, M | 2 |
| Im-erbsin, R | 2 |
| Tungtaeng, A | 1 |
| Saunders, D | 1 |
| Vanachayangkul, P | 1 |
| Imerbsin, R | 1 |
| Khemawoot, P | 1 |
| Siripokasupkul, R | 1 |
| Tekwani, BL | 2 |
| Sampath, A | 1 |
| Nanayakkara, NP | 1 |
| Lanteri, C | 1 |
| Gettyacamin, M | 1 |
| Teja-Isavadharm, P | 1 |
| Walker, L | 1 |
| Zanucoli, F | 1 |
| Bonfanti, AP | 1 |
| de Carvalho, AC | 1 |
| Issayama, LK | 1 |
| da Costa, TA | 1 |
| Di Gangi, R | 1 |
| Ferreira, IT | 1 |
| Bombeiro, AL | 1 |
| de Oliveira, AL | 1 |
| Verinaud, L | 1 |
| Mikolajczak, SA | 1 |
| Vaughan, AM | 1 |
| Kangwanrangsan, N | 1 |
| Roobsoong, W | 1 |
| Fishbaugher, M | 1 |
| Yimamnuaychok, N | 1 |
| Rezakhani, N | 1 |
| Lakshmanan, V | 1 |
| Singh, N | 1 |
| Kaushansky, A | 1 |
| Camargo, N | 1 |
| Baldwin, M | 1 |
| Lindner, SE | 1 |
| Adams, JH | 1 |
| Sattabongkot, J | 2 |
| Prachumsri, J | 1 |
| Kappe, SH | 1 |
| Jin, X | 1 |
| Nelson, J | 1 |
| Potter, C | 1 |
| Smith, PL | 1 |
| Paris, R | 1 |
| Marcsisin, SR | 3 |
| Wickham, KS | 1 |
| Baresel, PC | 1 |
| Vuong, CT | 1 |
| Reichard, GA | 1 |
| Campo, B | 1 |
| Duffier, Y | 1 |
| Lorthiois, A | 1 |
| Cisteró, P | 1 |
| Dupuy, F | 1 |
| Jouvion, G | 1 |
| Fiette, L | 1 |
| Mazier, D | 1 |
| Mayor, A | 1 |
| Lavazec, C | 1 |
| Moreno Sabater, A | 1 |
| Milner, EE | 1 |
| Dickson, SP | 1 |
| Lee, PJ | 1 |
| Read, LT | 1 |
| Vesely, BA | 1 |
| Xie, LH | 1 |
| Chattopadhyay, R | 1 |
| Velmurugan, S | 1 |
| Chakiath, C | 1 |
| Andrews Donkor, L | 1 |
| Milhous, W | 1 |
| Barnwell, JW | 2 |
| Collins, WE | 4 |
| Hoffman, SL | 1 |
| Sullivan, JS | 3 |
| Jeffery, GM | 1 |
| Nace, D | 1 |
| Williams, T | 1 |
| Galland, GG | 3 |
| Williams, A | 1 |
| Deye, GA | 1 |
| Hansukjariya, P | 1 |
| Rothstein, Y | 1 |
| Macareo, L | 1 |
| Fracisco, S | 1 |
| Bennett, K | 1 |
| Peters, W | 2 |
| Stewart, LB | 1 |
| Robinson, BL | 1 |
| Puri, SK | 2 |
| Dutta, GP | 1 |
| Singh, KK | 1 |
| Vingkar, SK | 1 |
| Zhang, JX | 1 |
| Huang, WZ | 1 |
| Ye, XY | 1 |
| Pan, YR | 1 |
| Luo, MZ | 1 |
| Lin, BY | 1 |
| Wang, LC | 1 |
| Steck, EA | 1 |
| Mayorga, P | 1 |
| Deharo, E | 1 |
| Landau, I | 1 |
| Couarraze, G | 1 |
| Nayar, JK | 1 |
| Baker, RH | 1 |
| Knight, JW | 1 |
| Morris, CL | 2 |
| Richardson, BB | 2 |
| Nguyen-Dinh, P | 1 |
| Nesby, S | 1 |
| Srivastava, P | 1 |
| Singh, S | 1 |
| Jain, GK | 1 |
| Pandey, VC | 1 |
| Rane, DS | 1 |
| Kinnamon, KE | 2 |
| Rossan, RN | 1 |
| Young, MD | 1 |
| Baerg, DC | 1 |
| Davidson, DE | 1 |
| Johnsen, DO | 1 |
| Tanticharoenyos, P | 1 |
| Hickman, RL | 1 |
| el-Mofty, MM | 1 |
| Khudoley, VV | 1 |
| Sakr, SA | 1 |
| Abdel-Gawad, HS | 1 |
| Queener, SF | 2 |
| Dean, RA | 1 |
| Bartlett, MS | 2 |
| Milhous, WK | 1 |
| Berman, JD | 1 |
| Ellis, WY | 1 |
| Smith, JW | 2 |
| Durkin, MM | 1 |
| Shaw, MA | 1 |
| Rastogi, M | 1 |
| Pal, NL | 1 |
| Sen, AB | 1 |
| Maronpot, RR | 1 |
| Scholnick, PL | 1 |
| Epstein, J | 1 |
| Marver, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779] | Phase 1 | 36 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for primaquine and Disease Models, Animal
| Article | Year |
|---|---|
The chemotherapy of protozoal infections: whither?
Topics: Animals; Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Disease Models, Animal; Glycolip | 1981 |
New answers through chemotherapy?
Topics: Aminoquinolines; Animals; Antimalarials; Chemical Phenomena; Chemistry; Disease Models, Animal; Drug | 1984 |
40 other studies available for primaquine and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and evaluation of naphthyridine compounds as antimalarial agents.
Topics: Animals; Antimalarials; Disease Models, Animal; Inhibitory Concentration 50; Malaria; Molecular Stru | 2007 |
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
Topics: Animals; Antimalarials; Disease Models, Animal; Enzyme Inhibitors; Fatty Acid Synthase, Type II; Hep | 2013 |
Structure-Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N-Aryl-3-trifluoromethyl Pyrido[1,2- a]benzimidazoles Which Are Efficacious in an in Vivo Mouse Model of Malaria.
Topics: Animals; Antimalarials; Benzimidazoles; Disease Models, Animal; Drug Design; ERG1 Potassium Channel; | 2019 |
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
Topics: Acridones; Animals; Antimalarials; Disease Models, Animal; Drug Discovery; Hep G2 Cells; Humans; Mal | 2019 |
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
Topics: Acridones; Administration, Oral; Animals; Antimalarials; Cell Survival; Disease Models, Animal; Fema | 2020 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Mechanisms of 8-aminoquinoline induced haemolytic toxicity in a G6PDd humanized mouse model.
Topics: Aminoquinolines; Animals; Antimalarials; Disease Models, Animal; Glucosephosphate Dehydrogenase Defi | 2022 |
Targeting liver stage malaria with metformin.
Topics: Animals; Antimalarials; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Drug | 2019 |
Primaquine elicits Foxp3
Topics: Animals; Antimalarials; Autoimmunity; Dendritic Cells; Disease Models, Animal; Encephalomyelitis, Au | 2020 |
An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolines.
Topics: Acute Disease; Aminoquinolines; Anemia, Hemolytic; Animals; Antimalarials; Chloroquine; Disease Mode | 2013 |
A primaquine-chloroquine hybrid with dual activity against Plasmodium liver and blood stages.
Topics: Animals; Antimalarials; Blood; Chimera; Chloroquine; Disease Models, Animal; Female; Liver; Malaria; | 2013 |
Causal prophylactic efficacy of primaquine, tafenoquine, and atovaquone-proguanil against Plasmodium cynomolgi in a rhesus monkey model.
Topics: Aminoquinolines; Animals; Antimalarials; Atovaquone; Disease Models, Animal; Drug Combinations; Maca | 2014 |
Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Administration Schedule; Drug Ther | 2014 |
Primaquine treatment suppresses experimental autoimmune encephalomyelitis severity.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Calcium-Binding Proteins; Central Nervous S | 2014 |
Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice.
Topics: Animals; Antimalarials; Chemoprevention; Chimera; Disease Models, Animal; Humans; Liver; Malaria, Vi | 2015 |
Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Topics: Animals; Antidepressive Agents; Antimalarials; Cells, Cultured; Cytochrome P-450 CYP2D6; Disease Mod | 2016 |
Single-Dose Primaquine in a Preclinical Model of Glucose-6-Phosphate Dehydrogenase Deficiency: Implications for Use in Malaria Transmission-Blocking Programs.
Topics: Animals; Antimalarials; Disease Models, Animal; Erythrocyte Transfusion; Erythrocytes; Glucosephosph | 2016 |
A humanized mouse model for sequestration of Plasmodium falciparum sexual stages and in vivo evaluation of gametocytidal drugs.
Topics: Animals; Antimalarials; Bone Marrow; Disease Models, Animal; Erythrocytes; Humans; Injections, Intra | 2016 |
Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei.
Topics: Aminoquinolines; Animals; Antimalarials; Chemoprevention; Cytochrome P-450 CYP2D6; Disease Models, A | 2016 |
Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria.
Topics: Animals; Anopheles; Antimalarials; Carcinoma, Hepatocellular; Cryopreservation; Disease Models, Anim | 2010 |
Mosquito infection studies with Aotus monkeys and humans infected with the Chesson strain of Plasmodiun vivax.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Disease Management; Disease Models, Animal; | 2012 |
Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Evaluation, Preclinical; Macaca mu | 2012 |
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug | 2003 |
Plasmodium cynomolgi: gametocytocidal activity of the anti-malarial compound CDRI 80/53 (elubaquine) in rhesus monkeys.
Topics: Animals; Anopheles; Antimalarials; Disease Models, Animal; Dose-Response Relationship, Drug; Female; | 2005 |
Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine.
Topics: Administration, Oral; Animals; Antimalarials; Disease Models, Animal; Drug Stability; Emulsions; Lip | 2008 |
[Establishment of monkey model of Plasmodium cynomolgi-Anopheles stephensi system and its use for tissue shizontocide test].
Topics: Animals; Anopheles; Antimalarials; Disease Models, Animal; Macaca; Macaca mulatta; Malaria; Plasmodi | 1982 |
Preliminary evaluation of primaquine activity on rodent malaria model after transdermal administration.
Topics: Administration, Cutaneous; Animals; Antimalarials; Disease Models, Animal; Drug Evaluation; Malaria; | 1997 |
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Brazil; Chloroquine; Disease Models, Animal; Drug Resist | 1997 |
Adaptation of a strain of Plasmodium vivax from Mauritania to New World monkeys and anopheline mosquitoes.
Topics: Adaptation, Physiological; Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Disease Models, | 1998 |
A simple and rapid evaluation of methemoglobin toxicity of 8-aminoquinolines and related compounds.
Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Animals; Antimalarials; Artemisini | 2000 |
The development of a "high volume tissue schizonticidal drug screen" based upon mortality of mice inoculated with sporozoites of Plasmodium berghei.
Topics: Animals; Antimalarials; Apicomplexa; Disease Models, Animal; Drug Evaluation, Preclinical; Haplorhin | 1979 |
Chemotherapy of Plasmodium vivax in Saimiri and Aotus models.
Topics: Administration, Oral; Animals; Chloroquine; Disease Models, Animal; Drug Combinations; Drug Evaluati | 1975 |
Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys.
Topics: Amodiaquine; Animals; Antimalarials; Dapsone; Disease Models, Animal; Dose-Response Relationship, Dr | 1976 |
The carcinogenicity of some antimalarial drugs using the Egyptian toad Bufo regularis as a biological test animal.
Topics: Animals; Antimalarials; Bufonidae; Chloroquine; Disease Models, Animal; Drug Combinations; Female; K | 1992 |
Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats.
Topics: Aminoquinolines; Animals; Clindamycin; Disease Models, Animal; Drug Administration Schedule; Female; | 1992 |
Inoculated mouse model of Pneumocystis carinii infection.
Topics: Aminoquinolines; Animals; Antimalarials; Clindamycin; Dexamethasone; Disease Models, Animal; Drug Th | 1992 |
Gametocytocidal and sporontocidal activity of some standard antimalarials on P. berghei (NK 65) infection M. natalensis.
Topics: Animals; Disease Models, Animal; Female; Malaria; Muridae; Plasmodium berghei; Primaquine; Pyrimetha | 1989 |
Erythrocyte glucose-6-phosphate dehydrogenase and glutathione deficiency in sheep.
Topics: Age Factors; Animals; Chromium Isotopes; Disease Models, Animal; Erythrocytes; Female; Glucosephosph | 1972 |
The molecular basis of the action of chloroquine in porphyria cutanea tarda.
Topics: 5-Aminolevulinate Synthetase; Animals; Chemical Phenomena; Chemistry; Chloroquine; Chromatography, G | 1973 |
Malaria research at the National Institute of Allergy and Infectious Diseases.
Topics: Animals; Chloroquine; Disease Models, Animal; Haplorhini; Humans; Malaria; National Institutes of He | 1969 |